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Coagulation factor IXThe interplay between impaired protein biosynthesis and/or function caused by missense muta-
tions, particularly in relation to speciﬁc protein regions, has been poorly investigated. As model
we chose the severe p.Y450C mutation in the carboxyl-terminal region of coagulation factor IX
(FIX) and, by expression of a panel of recombinant variants, demonstrated the key role of the tyro-
sine phenyl group for both FIX secretion and coagulant activity. Comparison among highly homol-
ogous coagulation serine proteases indicate that additive or compensatory pleiotropic effects on
secretion and function by carboxyl-terminal mutations produce life-threatening or mild pheno-
types in the presence of similarly reduced protein amounts.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The main mechanisms through which amino acid changes pro-
duce human disease forms consist of quantitative reduction of the
protein amount and/or synthesis of dysfunctional molecules. The
combination of these effects accounts for the overall extent of
the reduction of functional protein levels, which has major patho-
physiological relevance. However, due to the limited availability of
informative model mutations, the interplay between these patho-
genic molecular mechanisms has been poorly elucidated, particu-
larly in relation to speciﬁc protein regions.
The features of coagulation factor IX (FIX) deﬁciency (Hemo-
philia B) make this disorder an ideal model to address this issue.
The extensively characterized mutational pattern (http://www.fac-torix.org/)[1–3] of F9 gene [4] displays a large predominance of
missense mutations (>65%), mainly occurring in the chymotryp-
sin-like catalytic domain. Notwithstanding, only few pathogenic
molecular mechanisms have been detailed [5–8]. Strikingly, these
changes are responsible for the most variable clinical phenotypes,
ranging from asymptomatic to life-threatening conditions. It is
worth noting that Hemophilia B, having an X-linked inheritance
pattern, strongly favors the investigation of the relationship be-
tween molecular defects in the hemizygous condition and the
underlying residual function. The latter is of extreme importance
in bleeding disorders since even low amounts of functional protein
in plasma substantially ameliorate the bleeding phenotype in pa-
tients [9]. Moreover, being FIX a secreted serine protease, its pro-
tein concentration and enzymatic activity can be ﬁnely measured
by biochemical assays.
Within the family of the coagulation serine proteases, FIX is
highly homologous to factor VII (FVII), factor X (FX) and protein
C (PC) [10]. In spite of their similarities, these proteins display
remarkable differences both in length and amino acid composition
of the carboxyl-terminal region (Fig. 1), which could underlie dif-
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that the carboxyl-terminus has an essential role for the secretion of
FIX [11] and also of FVII [12] and PC [13]. On the other hand, alter-
ations in this region resulted in poor secretion of normal or hyper-
active variants of PC and FVII [14].
Taken together, these features make missense mutations in the
carboxyl-terminal region of coagulation factors of particular inter-
est for the investigation of the potential interplay between im-
paired biosynthesis and enzymatic function.
In this study, we characterized the p.Y450C missense change in
the carboxyl-terminus of FIX (chymotrypsin numbering c234). By
expression of a panel of recombinant FIX variants and evaluation
of the secreted protein and activitywe (i) dissected the contribution
of the p.Y450C missense change to the extent of reduction of func-
tional protein amounts, (ii) provided evidence for the crucial role of
the phenyl ring at this position in the FIX carboxyl-terminal region
and (iii) indicated major functional differences amongmutations in
the carboxyl-terminus of highly homologous serine proteases.
2. Materials and methods
2.1. Patient
The propositus was referred to the coagulation centre at 1 year
of age because of a spontaneous hematoma. Coagulation laboratory
assays indicated FIX coagulant (FIXc) activity below 1% and circu-
lating protein levels of 0.6% (30 ng/ml) of pooled normal plasma
(PNP). The family history of bleeding was negative. Upon develop-
ment of an initial target joint (left ankle), he entered prophylaxis
with recombinant FIX concentrate (Beneﬁx, Baxter, 50 IU/kg) once
a week, which prevented bleedings and the related complications.
Sequencing of F9 gene [4] identiﬁed the c.1349 A > G in exon 8
that predicts the Y450C amino acid substitution in the FIX serine
protease domain. This mutation has been previously found in se-
vere Hemophilia B patients with undetectable FIXc levels
[15,16].The parents gave informed consent to conduct the study,
which was in accordance with the Helsinki Declaration.
2.2. Expression vectors and transfection
Expression vectors for the recombinant FIX (rFIX) variants were
produced by site-directed mutagenesis using the QuickChange II
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The
mutations (referred as the underlined letter in the primer se-
quences) were introduced into the human FIX cDNA cloned into
the pCMV5 vector [8] using the following forward primers:
50CAAGGTATCCCGGTGTGTCAACTGG30 (Y450C), 50AAGGTATCCCGG
TCTGTCAAC30 (Y450S), and 50AAGGTATCCCGGTTTGTCAAC30
(Y450F). Reverse primers were complementary to the forward oli-
gonucleotides. Direct sequencing conﬁrmed the presence of the de-
sired mutations.
Expression vectors for FIX variants were transiently transfected
in Human Embryonic Kidney (HEK293) cells as previously de-
scribed [8]. Forty-eight hours later, conditioned media were col-
lected and cells lysed using a non-reducing lysis buffer (25 mM
Tris–phosphate, 10% glycerol, 1% Triton X-100, pH 7.8) supple-
mented with a protease inhibitor cocktail (Sigma–Aldrich, St. Louis,
MO, USA).
2.3. FIX protein and activity assays
FIX protein levels in plasma and in conditioned medium were
evaluated by ELISA (Afﬁnity Biologicals™ Inc., Canada) using serial
dilutions of a PNP as reference curve. Comparison with known
amounts of puriﬁed plasma-derived FIX (Haematologic TechnologiesInc., Essex Junction, VT, USA) indicated that FIX protein concentration
in the PNP aliquots used in all assays was 4.5 ± 0.1 lg/ml, and this
mean value was used to calculate the FIX concentration.
Western blotting analysis was conducted by SDS–PAGE on 4–
15% polyacrilamide precast gels (Bio-Rad, Hercules, CA, USA). A
HRP-conjugated polyclonal anti-human FIX antibody (Afﬁnity Bio-
logicals™ Inc.) and the enhanced chemiluminescence (ECL) reagent
(Pierce, Thermo Scientiﬁc, Rockford, IL, USA) were exploited for
the detection of rFIX proteins.
FIX coagulant activity in patient plasma was assessed by stan-
dard activated partial thromboplastin time (aPTT)-based coagula-
tion assays. To measure the coagulant activity of rFIX variants,
FIX-depleted plasma (HemosIL, Instrumentation Laboratory, Lex-
ington, MA, USA) was supplemented with rFIX-containing condi-
tioned medium followed by aPTT assays [17]. Coagulation times
were measured upon addition of a contact activator (SynthASil,
Hemosil) and CaCl2 on a ACLTOP700 instrument (Instrumentation
Laboratory). Coagulation times from serial dilutions of rFIX-wt
were used to create a standard curve, which was optimized for
the determination of low activity levels. The speciﬁc activity of rFIX
variants was calculated as the ratio between coagulant activity and
protein levels expressed as % of the rFIX-wt used in the coagulation
assays. To obtain the standard deviation, we assessed the activity
in media from three independent transfections for each mutant,
and each medium has been evaluated in duplicate.
3. Results and discussion
The F9 p.Y450C missense mutation identiﬁed by us in a Hemo-
philia B patient was chosen as model to investigate the interplay
between the pathogenic molecular mechanisms impairing protein
biosynthesis and enzymatic activity caused by alterations of the
variable carboxyl-terminus of coagulation serine proteases. We
took advantage from the expression of recombinant FIX variants
evaluated through immunological and coagulation assays, an ap-
proach that we previously exploited to dissect the molecular bases
of severe coagulation factor deﬁciency forms also caused by poten-
tially ‘‘null mutations’’ [8,14,18].
3.1. The disease-associated p.Y450C mutation reduces secretion of a
dysfunctional FIX molecule
Transient transfection experiments indicated that the introduc-
tion of the p.Y450C mutation into the human FIX cDNA (Fig. 1) re-
sulted in markedly reduced secreted amounts of rFIX-450C
molecules, as indicated by the protein concentration in medium
of 18.9 ± 6.2 ng/ml, corresponding to 4.9 ± 1.1% of those of rFIX-
wt (373.8 ± 119.6 ng/ml)(Fig. 2A).
The observation that protein concentration of the secreted rFIX-
450C variant was higher than that measured in patient plasma
(0.6% of PNP, 30 ng/ml) might underlie a reduced stability into
the circulation and/or a preferential removal of the FIX mutant
molecules in vivo, which cannot be properly assessed in cellular
models. On the other hand, the accumulation of the rFIX-450C in
medium may have led to overestimate the secreted levels. We
therefore conducted a time-course experiment. While the amount
of rFIX-wt was clearly appreciable in medium even at 6 h post-
transfection (3.4 ± 0.2 ng/ml), that of the rFIX-450C variant became
barely detectable only at 18 h and slowly increased over time
(Fig. 2B). This observation indicates a remarkable delayed secretion
of the mutant FIX and, taking into account the one day half-life of
FIX [19], provides a plausible explanation for the very low amount
of circulating FIX in the patient.
We subsequently assessed the impact of the amino acid change
on the FIX coagulant properties. To this purpose, we exploited
Fig. 1. Recombinant FIX variants and sequence alignment of highly homologous
coagulation factors. Schematic representation of the FIX structure with the natural
(in bold) and artiﬁcial amino acid substitutions reported on the top. LC, light chain;
HC, heavy chain. The box reports the sequence alignment of the carboxyl-terminal
region of FIX, FVII, PC and FX and the numbers indicate the protein residues
including the pre-propeptide sequence. The arrow indicates the position (c234,
chymotrypsin numbering) of the FIX mutation under study.
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ma with the rFIX-containing medium. Whereas the coagulation
time upon addition of 25 ng/ml of rFIX-wt was 88.0 ± 0.8 s, that
of a similar amount of rFIX-450C was prolonged (105.4 ± 3.3 s),
thus leading to estimate a speciﬁc activity of 0.14 ± 0.006 (Fig. 3A).
Taken together these data demonstrated that introduction of
cysteine at position 450 not only severely impairs biosynthesis
but also affects coagulant function, thus causing a severe Hemo-
philia B form.
3.2. The phenyl group of tyrosine 450 (c234) has a key role for
secretion and function
Analysis of the primary sequences of serine proteases revealed
that the phenyl group at position c234 is highly conserved [10].
Taking into account the highly homologous coagulation serine pro-
teases, tyrosine is present in FVII, FIX and PC but not in FX, which
displays phenylalanine (Fig. 1). Moreover, previous studies on the
rFIX-450H and rFIX-450P variants, whose secretion levels were re-
duced to 7% and undetectable [11], respectively, further support
the detrimental impact of amino acid changes at this position.Fig. 2. Expression levels of the recombinant FIX variants (A) Protein (white bars) and co
the percentage of rFIX-wt, and are reported as mean ± standard deviation from three inde
rFIX variants in cell lysates. MW, molecular weight marker. (B) Secreted levels of the rFI
experiments. Conditioned media were collected at 6, 18, 24, 30 and 48 h after transfectOn the other hand, inspection of the crystallographic structure of
activated FIX (ID 1RFN) suggests that tyrosine 450 is partially ex-
posed on the serine protease domain. The cysteine sulfhydryl
group introduced by the p.Y450C mutation could lead to illegiti-
mate disulﬁde bridges, and/or induce FIX dimerization in the endo-
plasmic reticulum, thus contributing to the biosynthetic
impairment. To address this issue, we performed Western blotting
analysis in non-reducing conditions of cell lysates, which did not
reveal FIX isoforms compatible with the presence of dimers
(Fig. 2A, inset). Moreover, we did not observe appreciable quantita-
tive differences between the rFIX-wt and rFIX-450C. This observa-
tion is consistent with the intracellular rFIX-450C levels measured
by ELISA (112.8 ± 2.6% of rFIX-wt), which excludes its intracellular
accumulation and is compatible with a quick degradation of the
mutant protein by the quality control system.
In an attempt to dissect the biochemical bases of our experi-
mental observations, we studied the effects on FIX biology of the
introduction of phenylalanine and serine (Fig. 1), maintaining the
phenyl ring or the oxydryl groups of tyrosine, respectively. Simi-
larly to the natural rFIX-450C variant, the secretion of the rFIX-
450S was markedly reduced (5.5 ± 0.2% of rFIX-wt) and delayed
(Fig. 2). At variance, the rFIX-450F was secreted in medium at
appreciable levels (25.3 ± 2.3%).
Functional assays in plasma systems revealed remarkable dif-
ferences among mutants. In particular, the speciﬁc activity of the
rFIX-450S (0.15 ± 0.05) was strongly reduced and comparable to
that of the natural rFIX-450C variant, while the rFIX-450F variant
displayed a virtually normal speciﬁc activity (0.78 ± 0.19) (Fig. 3A).
These ﬁndings indicate that the removal of the phenyl ring,
rather than the introduction of the sulfhydryl group, has the major
detrimental effect and is responsible for both impaired secretion
and dysfunctional FIX molecules. The importance of the phenyl
rings in the FIX carboxyl-terminus is further highlighted by the
observation that substitutions involving the other two tyrosine
residues of this region (p.Y441C and p.Y444S) are associated to
Hemophilia B [20,21]. However, the absence of information on
the circulating FIX protein levels in these patients does not permit
a proper comparison with the mutation under study.
Interestingly, for the mutations at position 450 not preserving
the phenyl ring the two detrimental effects on secretion and func-
tion were not disentangled. Their direct relation implies an addi-
tive behavior, which produces a steep gradient of function
impairment (Fig. 3A).agulant activity (grey bars) levels of secreted rFIX variants. Results are expressed as
pendent experiments. Inset. Western Blotting analysis in non-reducing conditions of
X-450C (j), rFIX-450S (h), rFIX-Y450F (s) and rFIX-wt (d) variants in time-course
ion. Protein levels are expressed as the log10 of concentration.
Fig. 3. Relationship between secreted protein levels and speciﬁc activity of FIX, FVII and PC carboxyl-terminal variants. The speciﬁc activity was calculated as the ratio
between activity and protein levels. The wild-type speciﬁc activity (referred as 1.00) is indicated by the dotted line. (A) FIX variants are: rFIX-wt (d), rFIX-450C (j), rFIX-450S
(h), rFIX-450F (.) and rFIX-450H variant (N) [11]; , rFIX-450P variant (not detectable, [11]). The rFIX-450C and rFIX-450S are superposed. The chemical structure of the side
chains at position 450 is displayed aside. (B) FVII variants are: rFVII-466X (h), rFIX-465X (s) rFVII-464X (}),rFVII-463X () rFVII-462A (s), rFVII-462 W (4), rFVII-462Q (r). ⁄,
gain-of-function R462X variant [14]. PC variants [13] are: rPC-459X (j), rPC-456X (.), rPC-453X (N) and rPC-452X (d). , further deletions of the PC carboxyl-terminus
resulted in undetectable secreted PC protein levels.
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of homologous coagulation serine proteases
The present ﬁndings on FIX differ substantially from our obser-
vations in FVII [14], and from those obtained in PC [13]. Indeed,
substitutions of R462 (c253) or short deletions at the FVII car-
boxyl-terminus resulted in reduced secreted levels of proteins with
normal speciﬁc activity (Fig. 3B). The R462X paradoxically dis-
played gain-of-function features that produced an asymptomatic
FVII deﬁciency form. Noticeably, these observations indicate that
additive or compensatory pleiotropic effects elicited by mutations
in the carboxyl-terminus of FIX and FVII, which similarly reduce
the circulating protein amount, give rise to life-threatening or mild
phenotypes. On the other hand, a deletion scanning of the car-
boxyl-terminal region of PC revealed that alterations of this protein
region have a major impact on secretion, as indicated by the nor-
mal speciﬁc activity of the secreted truncated PC variants (Fig. 3B).
Taken together these information suggest that the carboxyl-ter-
minal region of these highly homologous proteins [22] does not
represent a sole secretion determinant, but has a still undeﬁned
role for FIX and FVII function.
4. Conclusions
The study of model mutations in the carboxyl-terminus of FIX is
particularly informative to elucidate the interplay between patho-
genic molecular mechanisms impairing protein biosynthesis and
function. We provide evidence for a dual role of the FIX carboxyl-
terminus for both secretion and coagulant activity and for additive
effects of the p.Y450C mutation, which explain a particularly se-
vere Hemophilia B form. Comparison of ﬁndings in the highly
homologous coagulation serine protease family members suggests
that variations in this protein region might have contributed to the
evolution of this protein family sub-group.
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